

Possible collaboration with IMI CARE for late phase development of SARS-CoV-2/pan coronavirus antivirals and antibodies.

Have you developed a SARS-CoV-2 or potential broad-spectrum compound (small molecule or antibody) and need support with its characterisation, pre-clinical and/or early clinical testing? The CARE project has developed three platforms open to external collaboration to prepare the next generation of SARS-CoV-2/pan coronavirus antivirals/antibodies: an in vitro profiling platform, a pre-clinical in vivo platform and a clinical trial platform.

The CARE project

CARE (**C**orona **A**ccelerated **R**&**D** in **E**urope) is the largest initiative in Europe addressing the challenges of SARS-CoV-2, funded by the Innovative Medicines Initiative (IMI). The consortium collaborates as a public-private partnership with a coalition of 37 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China providing a multi-disciplinary team with proven scientific and technical expertise and capabilities in antiviral drug development.

The CARE consortium started in April 2020 and combines a focus on rapid emergency response with a focus on long-term preparedness for future outbreaks by addressing three main goals:

- The development of therapeutics to provide an emergency response towards the **current COVID-19 pandemic**
- The development of therapeutics to address the current and/or **future coronavirus outbreaks**.
- The understanding of the **physiopathology of COVID-19** and the discovery of immune markers contributing to the host immune responses to COVID-19 infection and their correlations with clinical and virological outcomes

The project ambition is to accelerate effective therapies for COVID-19 patients in Europe and around the world and generate a truly transformative treatment regimen.

More information on CARE can be found on its website: <https://www.imi-care.eu/>

Possible areas of collaboration

The CARE project is looking for promising SARS-CoV-2 and/or pan coronavirus antiviral compounds (small molecules and antibodies) to include in its pipeline. **Although CARE is particularly interested in clinic ready assets, the project can also provide support for pre-clinical phase of development.** CARE can help you with the development of your compound(s) by providing:

- A [clinical trial platform](#) of five centres in Europe with experience in clinical trials in infectious disease. The CARE project focuses on phase 1 and phase 2a trials
- Pre-clinical in vivo characterisation of small molecules and antibodies in hamster, mouse and non-human primate efficacy models against various SARS-CoV-2 variants.
- A well-developed platform of in vitro assays (viral yield assays, time of addition assays, assays to interrogate mode of action, etc.) for profiling of compounds(*) in different cell lines (e.g. VeroE6, A549, ex vivo broncheal and nasal epithelial cells) against different SARS-CoV-2 variants as well as other coronaviruses.

- A platform for the assessment of the inhibitory properties of compounds (*) in target-based assays and the study of the interaction of compounds(*) with their target.

**Please note that compounds already screened via ISIDORe will not be accepted to avoid duplication of effort.*

How to contact CARE

If you are interested, please contact us through the contact form: <https://www.imi-care.eu/contact/>

The CARE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and BILL & MELINDA GATES FOUNDATION, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE, UNIVERSITY OF DUNDEE.